These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 16977568)

  • 1. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):577-88. PubMed ID: 16977568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.
    Federici AB
    Hum Immunol; 2005 Apr; 66(4):422-30. PubMed ID: 15866707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired von Willebrand syndrome: features and management.
    Mohri H
    Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired von Willebrand syndrome: data from an international registry.
    Federici AB; Rand JH; Bucciarelli P; Budde U; van Genderen PJ; Mohri H; Meyer D; Rodeghiero F; Sadler JE;
    Thromb Haemost; 2000 Aug; 84(2):345-9. PubMed ID: 10959711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic lupus erythematosus complicated by acquired von Willebrand's syndrome.
    Hong S; Lee J; Chi H; Lee C; Nah S; Kim Y; Oh J; Moon H; Yoo B
    Lupus; 2008 Sep; 17(9):846-8. PubMed ID: 18755868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
    Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome.
    Luboshitz J; Lubetsky A; Schliamser L; Kotler A; Tamarin I; Inbal A
    Thromb Haemost; 2001 May; 85(5):806-9. PubMed ID: 11372672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus.
    Viallard JF; Pellegrin JL; Vergnes C; Borel-Derlon A; Clofent-Sanchez G; Nurden AT; Leng B; Nurden P
    Br J Haematol; 1999 May; 105(2):532-7. PubMed ID: 10233433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired von Willebrand's syndrome: a single institution experience.
    Kumar S; Pruthi RK; Nichols WL
    Am J Hematol; 2003 Apr; 72(4):243-7. PubMed ID: 12666134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome.
    van Genderen PJ; Boertjes RC; van Mourik JA
    Thromb Haemost; 1998 Sep; 80(3):495-8. PubMed ID: 9759633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart.
    Heilmann C; Geisen U; Beyersdorf F; Nakamura L; Benk C; Berchtold-Herz M; Trummer G; Schlensak C; Zieger B
    Thromb Haemost; 2010 May; 103(5):962-7. PubMed ID: 20352153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of acquired von Willebrand syndrome with AL amyloidosis.
    Kos CA; Ward JE; Malek K; Sanchorawala V; Wright DG; O'Hara C; Connors L; Skinner M; Seldin DC
    Am J Hematol; 2007 May; 82(5):363-7. PubMed ID: 17205535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.